These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10636569)

  • 1. Treatment of advanced prostate cancer: the vaccine approach.
    Mulders PF
    Scand J Urol Nephrol Suppl; 1999; 203():41-3. PubMed ID: 10636569
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy of prostate cancer.
    Doehn C
    Eur Urol; 2008 Apr; 53(4):681-3; discussion 684-5. PubMed ID: 18248878
    [No Abstract]   [Full Text] [Related]  

  • 3. [Vaccine therapy of prostate cancer].
    Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
    Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells and T cells in immunotherapy.
    O'Neill DW
    J Drugs Dermatol; 2010 Nov; 9(11):1383-92. PubMed ID: 21061761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers for the development of cancer vaccines: current status.
    Copier J; Whelan M; Dalgleish A
    Mol Diagn Ther; 2006; 10(6):337-43. PubMed ID: 17154650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of dendritic-cell based prostate cancer vaccine.
    Tjoa BA; Murphy GP
    Immunol Lett; 2000 Sep; 74(1):87-93. PubMed ID: 10996633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).
    Harzstark AL; Small EJ
    Expert Opin Biol Ther; 2007 Aug; 7(8):1275-80. PubMed ID: 17696825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies.
    Essand M
    Acta Oncol; 2005; 44(6):610-27. PubMed ID: 16165921
    [No Abstract]   [Full Text] [Related]  

  • 11. Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects.
    Minev BR; Guo F; Gueorguieva I; Kaiser HE
    In Vivo; 2002; 16(6):405-15. PubMed ID: 12494883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer.
    He Q; Li J; Yin W; Song Z; Zhang Z; Yi T; Tang J; Wu D; Lu Y; Wang Z; Liu D; Zhang X; Hu Z; Gao J
    Cancer Immunol Immunother; 2011 May; 60(5):715-30. PubMed ID: 21331814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
    Sims RB
    Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In situ vaccination for the treatment of cancer.
    Hammerich L; Bhardwaj N; Kohrt HE; Brody JD
    Immunotherapy; 2016; 8(3):315-30. PubMed ID: 26860335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
    Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
    Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approach for prostate cancer vaccine development.
    ACS Chem Biol; 2011 Nov; 6(11):1141-2. PubMed ID: 22091902
    [No Abstract]   [Full Text] [Related]  

  • 17. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
    Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
    Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
    Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
    Arlen PM; Gulley JL; Tsang KY; Schlom J
    Expert Rev Vaccines; 2003 Aug; 2(4):483-93. PubMed ID: 14711334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yeast-based identification of prostate tumor antigens provides an effective vaccine platform.
    Jung V; Fischer E; Imig J; Kleber S; Nuber N; Reinshagen F; Kamradt J; Grobholz R; Knuth A; Renner C; Wadle A
    Anticancer Res; 2010 Mar; 30(3):895-902. PubMed ID: 20393012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.